Puma Biotechnology announces presentation of findings from a phase II study of alisertib in endocrine-resistant metastatic breast cancer Read more
IGNAZ trial interim results highlight HI-Bio’s potential to differentiate in IgAN space: GlobalData Read more
GLP-1R agonists’ type 2 diabetes and obesity market to reach $125 billion in 7MM by 2033: GlobalData Read more